Therapeutic drug monitoring of antidepressants. Cost implications and relevance to clinical practice

Clinical Pharmacokinetics

Volumn 37, Issue 2, 1999, Pages 147-165

  Burke, Michael J ^a   Preskorn, Sheldon H ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; FLUOXETINE; FLUVOXAMINE; ISOCARBOXAZID; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; PAROXETINE; PHENELZINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG TISSUE LEVEL; HEALTH CARE COST; HUMAN; HYPERTENSION; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SEROTONIN SYNDROME;

ANTIDEPRESSIVE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; HUMANS; PHARMACOGENETICS;

EID: 0032847652     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199937020-00004     Document Type: Review

References (87)

1. Burke MJ, Preskorn SH. Short-term treatment of affective disorders using standard antidepressants. In: Watson SJ, editor. Psychopharmacology: CD-ROM. New York: Lippincott-Raven Press, 1999
2. Burke MJ. The search for value: Issues in the treatment of depression. J Pract Psychiatry Behav Health 1996; 2: 2-13
3. Preskorn SH. Why did Terry fall off the dose-response curve? J Pract Psychiatry Behav Health 1996; 2 (1): 39-43
4. Burke MJ, Silkey B, Preskorn SH. Pharmacoeconomic considerations when evaluating treatment options for major depressive disorder. J Clin Psychiatry 1994; 55 (9 Suppl. A): 42-52
5. Preskorn SH, Burke, MJ, Fast GA. Therapeutic drug monitoring: principles and practice. Psychiatr Clin North Am 1993; 16 (3): 611-45
6. Amsterdam JD, Fawcett J, Quitkin FM, et al. Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study. Am J Psychiatry 1997; 154: 963-9
7. Preskorn SH. Pharmacokinetics of antidepressants: why and how are they relevant to treatment. J Clin Psychiatry 1993; 54 (9 Suppl.): 14-34
8. Preskorn SH. Should bupropion dosage be adjusted based upon therapeutic drug monitoring? Psychopharmacol Bull 1991; 27 (4): 637-43
9. Preskorn SH. To monitor or not to monitor, II: the glass is more than half full. J Prac Psychiatry Behav Health 1996; 2 (5): 307-10
10. Guthrie S, Lane EA, Linnoila M. Monitoring of plasma drug concentrations in clinical psychopharmacology. In: Meltzer HY, editor. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987: 1323-38
11. Glotzbach RK, Preskorn SH. Brain concentrations of tricyclic antidepressants: single dose kinetics and relationship to plasma concentration in chronically dosed rats. Psychopharmacology 1982; 78: 25-7
12. Karson CN, Newton JE, Livingston R, et al. Human brain fluoxetine concentrations. J Neuropsychiatry Clin Neurosci 1993; 5: 322-9
13. Renshaw PF, Guimaraes AR, Fava M, et al. Accumulation of fluoxetine and norfluoxeline in human brain during therapeutic administration. Am J Psychiatry 1992; 149: 1592-4
14. Greenblatt DJ, Harmatz JS. Kinetic-dynamic modeling in clinical psychopharmacology. J Clin Psychopharmacol 1993; 13 (4): 231-4
15. Yesavage JA. Psychotropic blood levels: a guide to clinical response. J Clin Psychiatry 1986; 47 (9 Suppl.): 16-9
16. Ley P. Satisfaction, compliance and communication. Br J Clin Psychol 1981; 21: 241-4
17. Lin EHB, Von Korff M, Katon W, et al. The role of the primary care physician in patient's adherence to antidepressant therapy. Med Care 1995; 33: 67-74
18. Preskorn SH, Fast GA. Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost-effectiveness. J Clin Psychiatry 1991: 52 (6 Suppl.): 23-33
19. Goldman DL, Katz SE, Preskorn SH. What to do about extremely high plasma levels of tricyclics? Am J Psychiatry 1989; 146: 401-2
20. Richelson E. Pharmacology of antidepressants: characteristics of the ideal drug. Mayo Clin Proc 1994; 69: 1069-81
21. Bolden-Watson C, Richelson E. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 1993; 52: 1023-9
22. Preskorn SH. Antidepressant drug selection: criteria and options. J Clin Psychiatry 1994; 55 (9 Suppl. A): 6-22
23. Jerling M. Dosing of antidepressants: the unknown art. J Clin Psychopharmacol 1995; 15: 435-9
24. Depression Guideline Panel of the Agency for Health Care Policy and Research: synopsis of the clinical practice guidelines for diagnosis and treatment of depression in primary care. Arch Fam Mod 1994; 3: 85-92
25. Quitkin FM, McGrath PJ, Stewart JW, et al. Chronological milestones to guide drug change: when should clinicians switch antidepressants? Arch Gen Psychiatry 1996; 53: 785-92
26. Balant-Gorgia AE, Balant LP, Garrone G. High blood concentrations of imipramine and clomipramine and therapeutic failure: a case report study using drug monitoring data. Ther Drug Monit 1989; 11: 415-20
27. Preskorn SH, Jerkovich GS. Central nervous system toxicity of tricyclic antidepressants: phenomenology, course, risk factors, and role of therapeutic drug monitoring. J Clin Psychopharmacol 1990; 10: 88-95
28. Preskorn SH. Clinical pharmacology of selective serotonin reuptake inhibitors. Caddo (OK): Professional Communications, Inc., 1996: 99-105
29. Burghart SM. 1997: the year in review. Drug Utilization Rev Bull 1998: 20 (1): 1-2
30. Janicak PG, Davis JM, Preskorn SH, et al. Principles and practice of psychopharmacotherapy. 2nd ed. Baltimore (MD): Williams and Wilkens, 1997: 61-82
31. Dornseif BE, Dunlop SR, Potvin JH, et al. Effect of dose escalation after low-dose fluoxetine therapy. Psychopharmacol Bull 1989; 25: 71-9
32. Cain JW. Poor response to fluoxetine: underlying depression, serotonergic overstimulation, or a therapeutic window? J Clin Psychiatry 1992; 53: 272-7
33. Fabre LF, Abuzzahab FS, Amin M, et al. Sertraline safety and efficacy in major depression, a double-blind fixed dose comparison with placebo. Biol Psychiatry 1995; 38: 592-602
34. Preskorn SH. Clinically relevant pharmacology of the selective serotonin reuptake inhibitors: an overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism Clin Pharmacokinet 1997; 32 Suppl. 1: 1-21
35. Preskorn SH, Fast GA. Tricyclic antidepressant-induced seizures and plasma drug concentration. J Clin Psychiatry 1992; 53 (5): 160-2
36. Preskorn SH, Weller E, Weller R, et al. Plasma levels of imipramine and adverse effects in children. Am J Psychiatry 1983; 140: 1332-5
37. Rudorfer MB, Young RC. Desipramine: cardiovascular effects and plasma levels. Am J Psychiatry 1980; 137: 984-6
38. Veith RC, Friedel RO, Bloom B, et al. Electrocardiogram changes and plasma desipramine levels during treatment. Clin Pharmacol Ther 1980; 27: 796-802
39. Preskorn SH, Jerkovich GS, Beber JH, et al. Therapeutic drug monitoring of tricyclic antidepressants: a standard of care issue. Psychopharmacol Bull 1989; 25: 281-4
40. Goodnick PJ. Pharmacokinetic optimisation of therapy with newer antidepressants. Clin Pharmacokinet 1994; 27 (4): 307-30
41. Perry PJ, Pfohl BM, Holstad SG. The relationship between antidepressant response and tricyclic antidepressant plasma concentrations. Clin Pharmacokinet 1987; 13: 381-92
42. Olfson M, Klerman GL. Trends in the prescription of antide-pressants by office-based psychiatrists. Am J Psychiatry 1993; 150: 571-7
43. Beasley C, Dornseif B, Pultz J, et al. Fluoxetine versus trazodone: efficacy and activating sedating effects. J Clin Psychiatry 1991; 52: 294-9
44. Carraci G. Unsuccessful suicide attempt by sertraline overdose [letter]. Am J Psychiatry 1994; 151: 147
45. Dunner DL, Dunbar GC. Optimal dose regimen for paroxetine. J Clin Psychiatry 1992; 53 Suppl. 2: 21-6
46. Wernicke JF, Dunlop SR, Dornseif BE, et al. Fixed dose fluoxetine therapy for depression. Psychopharmacol Bull 1987; 23: 164-8
47. Preskorn SH, Harvey A. Biochemical and clinical dose-response curves with sertraline. Clin Pharmacol Ther 1996; 59: 180
48. Wenicke JF, Dunlop SR, Dornseif BE, et al. Low-dose fluoxetine therapy for depression. Psychopharmacol Bull 1988; 24: 183-8
49. Schweizer E, Rickels K, Amsterdam J, et al. What constitutes an adequate antidepressant trial for fluoxetine. J Clin Psychiatry 1990; 51: 8-11
50. Altamura A, Montgomery S, Wernicke J. The evidence for 20 mg a day of fluoxetine as the optimal in the treatment of depression. Br J Psychiatry 1988; 153 Suppl. 3: 109-12
51. Tasker T, Kaye C, Zussman D, et al. Paroxetine plasma levels: lack of correlation with efficacy or adverse events. Acta Psychiatr Scand 1990: 80 Suppl. 350: 152-5
52. Lemberger L, Bergstrom R, Wolen R, et al. Fluoxetine. Clinical pharmacology and physiologic disposition. J Clin Psychiatry 1985; 46 (3 Sect. 2): 14-9
53. Wood K, Swade C, Abou-Sach M, et al. Drug plasma levels and platelet 5-HT uptake inhibition during long-term treatment with fluvoxamine or lithium in patients with affective disorders. Br J Clin Pharmacol 1983; 15 Suppl. 3: 365S-8S
54. Marsden CA, Tyrer P, Casey P, et al. Changes in human whole blood 5-hydroxytrypamine (5-HT) and platelet 5-HT uptake during treatment with paroxetine, a selective 5-HT uptake inhibitor. J Psychopharmacol 1987; 1: 244-50
55. Thase ME, Kupfer DJ. Recent developments in the pharmacotherapy of mood disorders. J Consult Clin Psychol 1996; 64 (4): 646-59
56. Preskorn SH, Silkey B, Beber J, et al. Antidepressant response and plasma concentration of fluoxetine. Ann Clin Psychiatry 1991; 3 (2): 147-51
57. Kelly M, Perry P, Holstead S, et al. Serum fluoxetine and norfluoxetine concentration and antidepressant response. Ther Drug Monit 1989; 11: 165-70
58. Koran LM, Cain JW, Dominguez RA, et al. Are fluoxeline plasma levels related to outcome in obsessive compulsive disorder? Am J Psychiatry 1996; 153: 1450-4
59. Preskorn SH, Alderman J, Chung M, et al. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 1994; 14: 90-8
60. Ronfeld RA, Tremaine LM, Wilner KD, et al. Evaluation of the pharmacokinetic properties of sertraline and desmethylsertraline in elderly and young male and female volunteers. Clin Pharmacokinet 1997; 32 Suppl. 1: 22-30
61. Bayer AJ, Roberts NA, Allen EA, et al. The pharmacokinetics of paroxetine in the elderly. Acta Psychiatr Scand 1989; 80 Suppl. 350: 85-6
62. Hebenstreit GF, Fellerer K, Zochling R, et al. A pharmacokinetic dose titration study in adult and elderly depressed patients. Acta Psychiatr Scand 1989; 80 Suppl. 350: 81-4
63. Lund J, Lomholt B, Fabricius J, et al. Paroxctine, pharmacokinetics, tolerance and depletion of blood 5-HT in man. Acta Pharmacol Toxicol 1979; 44: 289-95
64. Lundmark J, Scheel K, Thomsen I, et al. Paroxetine: pharmacokinetics and antidepressant effect in the elderly. Acta Psychiatr Scand 1989; 80 Suppl. 350: 76-80
65. Sindrup SH, Brosen K, Gram LF. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the spartiene oxidation polymorphism. Clin Pharm Ther 1992; 51: 288-95
66. Feighner JP, Cohn JB. Double blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. J Clin Psychiatry 1985; 46: 20-5
67. Goodnick PJ. Pharmacokinetics of second generation antidepressants: fluoxeline. Psychopharm Bull 1991; 27 (4): 503-12
68. Goodnick PJ. Fluoxetine blood levels and clinical response [abstract]. Biol Psychiatry 1992; 31: 186A
69. Bjerkenstedt L, Flyekt L, Overo KF, et al. Relationship between clinical effects, serum drug concentration and serotonin uptake inhibition in depressed patients treated with citalopram: a double-blind comparison of three dose levels. Eur J Clin Pharmacol 1985; 28: 553-7
70. Fredricson OK. Kinetics of citalopram in man: plasma levels in patients. Prog Neuropsychopharmacol Biol Psychiatry 1982; 6: 311-8
71. Kragh-Sorenson P, Overo KF, Peterson OL, et al. The kinetics of citalopram single and multiple dose studies in man. Acta Pharmacol Toxicol 1981; 48: 53-60
72. Rochat B, Amey M, Bauman P. Analysis of enantiomers of citalopram and its demethylated metabolites in plasma of depressive patients using chiral reverse-phase liquid chromalography. Ther Drug Monit 1995; 17: 273-9
73. Folgia JP, Perel JM, Nathan RS, et al. Therapeulic drug monitoring of fluvoxamine, a selective antidepressant [abstract]. Clin Chem 1990; 36: 1043
74. Nathan RS, Perel JM, Pollock BG, et al. The role of neuropharmacologic selectivity in antidepressant action. Fluvoxamine versus desipramine. J Clin Psychiatry 1990; 51: 367-72
75. Cooper TB, Suckow RF, Glassman A. Determination of bupropion and its major basic metabolites in plasma by liquid chromatography with dual wavelength U.V. detection. J Pharm Sci 1984; 73: 1104-7
76. Perumal AS, Smith TM, Suckow RF. et al. Effects of plasma from patients containing bupropion and its metabolites on the uptake of norepincphrine. Neuropharmacology 19986; 25: 199-202
77. Preskorn S, Katz S. Bupropion plasma levels: intraindividual and interindividual variability. Ann Clin Psychiatry 1989; 1: 59-61
78. Goodnick PJ. Pharmacokinetics of second generation antidepressants: bupropion. Psychopharmacol Bull 1991; 27 (4): 513-9
79. Goodnick PJ. Blood levels and acute response to bupropion. Am J Psychiatry 1992; 149 (3): 399-400
80. Golden RN, DeVane CL, Laizure SC, et al. Bupropion in depression: II. The roles of metabolites in clinical outcome. Arch Gen Psychiatry 1988; 45: 145-9
81. Davidson J. Seizures and bupropion: a review. J Clin Psychaitry 1989; 50: 256-61
82. Preskorn SH, Fleck RJ, Schroeder DH. Therapeutic drug monitoring of bupropion. Am J Psychiatry 1990; 147 (12): 1690-1
83. Klamerus KJ, Maloney K, Rudolph RL, et al. Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. J Clin Pharmacol 1992; 32: 716-24
84. Haskins JT, Moyer JA, Muth EA, et al. DMI, WY-45,030, WY45,881 and ciramadol inhibit locus ceruleus neuronal activity. Eur J Pharmacol 1985; 115: 139-46
85. Harvey A, Preskorn S. Mechanism of action of venlafaxine in normal male volunteers. Clin Pharm Ther 1997: 61 (2): 175
86. Preskorn SH. Selection of an antidepressant: mirtazapine. J Clin Psychiatry 1997; 58 Suppl. 6: 3-8
87. Preskorn SH, Burke MJ. Somatic therapy for major depressive disorder: selection of an antidepressant. J Clin Psychiatry 1992; 53 (9 Suppl.): 5-18